135 related articles for article (PubMed ID: 25791581)
1. Evaluation of the serum matrix metalloproteinase-9 as a biomarker for monitoring disease progression in Duchenne muscular dystrophy.
Zocevic A; Rouillon J; Wong B; Servais L; Voit T; Svinartchouk F
Neuromuscul Disord; 2015 May; 25(5):444-6. PubMed ID: 25791581
[No Abstract] [Full Text] [Related]
2. Response to: Evaluation of the serum matrix metalloproteinase-9 as a biomarker for monitoring disease progression in Duchenne muscular dystrophy.
Spitali P; Aartsma-Rus A; 't Hoen PA
Neuromuscul Disord; 2015 May; 25(5):446-7. PubMed ID: 25795139
[No Abstract] [Full Text] [Related]
3. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD).
Nadarajah VD; van Putten M; Chaouch A; Garrood P; Straub V; Lochmüller H; Ginjaar HB; Aartsma-Rus AM; van Ommen GJ; den Dunnen JT; 't Hoen PA
Neuromuscul Disord; 2011 Aug; 21(8):569-78. PubMed ID: 21724396
[TBL] [Abstract][Full Text] [Related]
4. Serum Osteopontin as a Novel Biomarker for Muscle Regeneration in Duchenne Muscular Dystrophy.
Kuraoka M; Kimura E; Nagata T; Okada T; Aoki Y; Tachimori H; Yonemoto N; Imamura M; Takeda S
Am J Pathol; 2016 May; 186(5):1302-12. PubMed ID: 26963343
[TBL] [Abstract][Full Text] [Related]
5. Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy.
Strandberg K; Ayoglu B; Roos A; Reza M; Niks E; Signorelli M; Fasterius E; Pontén F; Lochmüller H; Domingos J; Ala P; Muntoni F; Aartsma-Rus A; Spitali P; Nilsson P; Szigyarto CA
J Neuromuscul Dis; 2020; 7(3):231-246. PubMed ID: 32390640
[TBL] [Abstract][Full Text] [Related]
6. Increased matrix-metalloproteinase-2 and matrix-metalloproteinase-9 expression in the brain of dystrophic mdx mouse.
Nico B; Corsi P; Ria R; Crivellato E; Vacca A; Roccaro AM; Mangieri D; Ribatti D; Roncali L
Neuroscience; 2006 Jul; 140(3):835-48. PubMed ID: 16650610
[TBL] [Abstract][Full Text] [Related]
7. Breathe Duchenne: what natural history studies tell us about the progression of pulmonary morbidity in Duchenne muscular dystrophy.
Mayer OH; Aliverti A; Meier T
Neuromuscul Disord; 2018 Nov; 28(11):910-913. PubMed ID: 30266222
[No Abstract] [Full Text] [Related]
8. Influence of disease progression on the neuromuscular blocking effect of mivacurium in children and adolescents with Duchenne muscular dystrophy.
Ihmsen H; Schmidt J; Schwilden H; Schmitt HJ; Muenster T
Anesthesiology; 2009 May; 110(5):1016-9. PubMed ID: 19352159
[TBL] [Abstract][Full Text] [Related]
9. Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy.
Hu J; Kong M; Ye Y; Hong S; Cheng L; Jiang L
J Neurochem; 2014 Jun; 129(5):877-83. PubMed ID: 24460924
[TBL] [Abstract][Full Text] [Related]
10. Physical Activity in Boys With Duchenne Muscular Dystrophy Is Lower and Less Demanding Compared to Healthy Boys.
Heutinck L; Kampen NV; Jansen M; Groot IJ
J Child Neurol; 2017 Apr; 32(5):450-457. PubMed ID: 28112012
[TBL] [Abstract][Full Text] [Related]
11. Early symptoms of Duchenne muscular dystrophy--description of cases of an 18-month-old and an 8-year-old patient.
Iwańczak F; Stawarski A; Potyrała M; Siedlecka-Dawidko J; Agrawal GS
Med Sci Monit; 2000; 6(3):592-5. PubMed ID: 11208376
[TBL] [Abstract][Full Text] [Related]
12. True euglycemic diabetic ketoacidosis in a person with type 2 diabetes and Duchenne muscular dystrophy.
Lee SH; Park JH; Hong MK; Hyeon S; Kim MY; Lee SE; Ahn J; Kim J
Diabetes Res Clin Pract; 2011 Apr; 92(1):e7-8. PubMed ID: 21216484
[TBL] [Abstract][Full Text] [Related]
13. Progressive respiratory insufficiency in the absence of cardiac disease in late-stage Duchenne muscular dystrophy.
Finsterer J; Stöllberger C; Meng G
Respir Care; 2013 Mar; 58(3):e28-30. PubMed ID: 22781000
[No Abstract] [Full Text] [Related]
14. Strong correlation between the 6-minute walk test and accelerometry functional outcomes in boys with Duchenne muscular dystrophy.
Davidson ZE; Ryan MM; Kornberg AJ; Walker KZ; Truby H
J Child Neurol; 2015 Mar; 30(3):357-63. PubMed ID: 24762862
[TBL] [Abstract][Full Text] [Related]
15. Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy.
Zschüntzsch J; Zhang Y; Klinker F; Makosch G; Klinge L; Malzahn D; Brinkmeier H; Liebetanz D; Schmidt J
J Neurochem; 2016 Jan; 136(2):351-62. PubMed ID: 26230042
[TBL] [Abstract][Full Text] [Related]
16. Flow Cytometry-Defined CD49d Expression in Circulating T-Lymphocytes Is a Biomarker for Disease Progression in Duchenne Muscular Dystrophy.
Savino W; Pinto-Mariz F; Mouly V
Methods Mol Biol; 2018; 1687():219-227. PubMed ID: 29067667
[TBL] [Abstract][Full Text] [Related]
17. Three-point technique of fat quantification of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: preliminary study.
Wren TA; Bluml S; Tseng-Ong L; Gilsanz V
AJR Am J Roentgenol; 2008 Jan; 190(1):W8-12. PubMed ID: 18094282
[TBL] [Abstract][Full Text] [Related]
18. The role of corticosteroids in Duchenne muscular dystrophy: a review for the anesthetist.
Ames WA; Hayes JA; Crawford MW
Paediatr Anaesth; 2005 Jan; 15(1):3-8. PubMed ID: 15649156
[No Abstract] [Full Text] [Related]
19. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
[TBL] [Abstract][Full Text] [Related]
20. Serum creatinine level: a supplemental index to distinguish Duchenne muscular dystrophy from Becker muscular dystrophy.
Zhang H; Zhu Y; Sun Y; Liang Y; Li Y; Zhang Y; Deng L; Wen X; Zhang C
Dis Markers; 2015; 2015():141856. PubMed ID: 25852218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
